{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:50:20Z","timestamp":1788385820949,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12032-018-1188-2","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T10:52:40Z","timestamp":1534416760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients"],"prefix":"10.1007","volume":"35","author":[{"given":"Akie","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3679-4290","authenticated-orcid":false,"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"1188_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2014","unstructured":"Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2014;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"1188_CR2","first-page":"295","volume":"3","author":"H Hameed","year":"2011","unstructured":"Hameed H, Cassidy J. Use of capecitabine in management of early colon cancer. Cancer Manag Res. 2011;3:295\u20139.","journal-title":"Cancer Manag Res"},{"key":"1188_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.clcc.2014.01.001","volume":"13","author":"JM Loree","year":"2014","unstructured":"Loree JM, Mulder KE, Ghosh S, Spratlin JL. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer. Clin Colorectal Cancer 2014;13:172\u20137. \n                    https:\/\/doi.org\/10.1016\/j.clcc.2014.01.001\n                    \n                  .","journal-title":"Clin Colorectal Cancer"},{"key":"1188_CR4","first-page":"1669","volume":"26","author":"AS Ardavanis","year":"2006","unstructured":"Ardavanis AS, Ioannidis GN, Orphanos GS, Rigatos GA. Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Res. 2006;26:1669\u201372.","journal-title":"Anticancer Res"},{"key":"1188_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12885-016-2113-8","volume":"16","author":"A Stein","year":"2015","unstructured":"Stein A, Quidde J, Schroder JK, Gohler T, Tschechne B, Valdix A-R, et al. Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer\u2014results from a non-interventional observation study. BMC Cancer 2015;16:82. \n                    https:\/\/doi.org\/10.1186\/s12885-016-2113-8\n                    \n                  .","journal-title":"BMC Cancer"},{"key":"1188_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.03.074","volume":"61","author":"FN Erning Van","year":"2016","unstructured":"Van Erning FN, Razenberg LGEM, Lemmens VEPP, Creemers GJ, Pruijt JFM, Maas HAAM, et al. Intensity of adjuvant chemotherapy regimens and grade III\u2013V toxicities among elderly stage III colon cancer patients. Eur J Cancer 2016;61:1\u201310. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.03.074\n                    \n                  .","journal-title":"Eur J Cancer"},{"key":"1188_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1463-1318.2009.01879.x","volume":"12","author":"G Zhao","year":"2010","unstructured":"Zhao G, Gao P, Yang KH, Tian JH, Ma B. Capecitabine\/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis. Color Dis. 2010;12:615\u201323.","journal-title":"Color Dis"},{"key":"1188_CR8","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1007\/s10350-007-9045-y","volume":"50","author":"C-C Law","year":"2007","unstructured":"Law C-C, Fu Y-T, Chau K-K, Choy T-S, So P-F, Wong K-H. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. Dis. Colon Rectum 2007;50:2180\u20137.","journal-title":"Dis. Colon Rectum"},{"key":"1188_CR9","first-page":"1653","volume":"27","author":"GP Stathopoulos","year":"2007","unstructured":"Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J, Deliconstantinos G. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects. Anticancer Res. 2007;27:1653\u20136.","journal-title":"Anticancer Res"},{"key":"1188_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4137\/CMO.S8194","volume":"6","author":"J Quidde","year":"2012","unstructured":"Quidde J, Arnold D, Stein A. Clinical management of localized colon cancer with capecitabine. Clin Med Insights Oncol. 2012;6:363\u201373.","journal-title":"Clin Med Insights Oncol"},{"key":"1188_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/ajco.12409","volume":"11","author":"YS Park","year":"2015","unstructured":"Park YS, Ji J, Zalcberg JR, El-Serafi M, Buzaid A, Ghosn M. Oxaliplatin\/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: outcomes of the ACCElox Registry. Asia\u2013Pac J Clin Oncol. 2015;11:334\u201342.","journal-title":"Asia\u2013Pac J Clin Oncol"},{"key":"1188_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.clcc.2014.06.002","volume":"13","author":"CAK Kim","year":"2014","unstructured":"Kim CAK, Spratlin JL, Armstrong DE, Ghosh S, Mulder KE. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian Cancer Institute experience. Clin Colorectal Cancer 2014;13:199\u2013206. \n                    https:\/\/doi.org\/10.1016\/j.clcc.2014.06.002\n                    \n                  .","journal-title":"Clin Colorectal Cancer"},{"key":"1188_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.clcc.2015.09.002","volume":"15","author":"JJ Ko","year":"2016","unstructured":"Ko JJ, Kennecke HF, Lim HJ, Renouf DJ, Gill S, Woods R, et al. Reasons for underuse of adjuvant chemotherapy in elderly patients with stage III colon cancer. Clin Colorectal Cancer 2016;15:179\u201385. \n                    https:\/\/doi.org\/10.1016\/j.clcc.2015.09.002\n                    \n                  .","journal-title":"Clin Colorectal Cancer"},{"key":"1188_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clcc.2012.09.001","volume":"12","author":"NJ McCleary","year":"2013","unstructured":"McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer 2013;12:62\u20139. \n                    https:\/\/doi.org\/10.1016\/j.clcc.2012.09.001\n                    \n                  .","journal-title":"Clin Colorectal Cancer"},{"key":"1188_CR15","first-page":"1","volume":"22","author":"AI Ilich","year":"2015","unstructured":"Ilich AI, Danilak M, Kim C, Mulder KE, Spratlin JL, Ghosh S, et al. Effects of gender on capecitabine toxicity in colorectal cancer. J Oncol Pharm Pract. 2015;22:1\u20137.","journal-title":"J Oncol Pharm Pract"},{"key":"1188_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/cam4.621","volume":"5","author":"R Ali","year":"2016","unstructured":"Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, et al. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. 2016;5:607\u201316.","journal-title":"Cancer Med"},{"key":"1188_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s12094-015-1408-6","volume":"18","author":"M Ozcelik","year":"2016","unstructured":"Ozcelik M, Odabas H, Ercelep O, Yuksel S, Mert AG, Aydin D, et al. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients. Clin Transl Oncol. 2016;18:617\u201324.","journal-title":"Clin Transl Oncol"},{"key":"1188_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CAD.0b013e3283417f3e","volume":"22","author":"E Vrdoljak","year":"2011","unstructured":"Vrdoljak E, Omr\u010den T, Boban M, Hrabar A. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer. Anticancer Drugs 2011;22:191\u20137.","journal-title":"Anticancer Drugs"},{"key":"1188_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2003.07.125","volume":"21","author":"JA Meyerhardt","year":"2003","unstructured":"Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21:433\u201340.","journal-title":"J Clin Oncol"},{"key":"1188_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12957-015-0488-7","volume":"13","author":"MS An","year":"2015","unstructured":"An MS, Yoo JH, Kim KH, Bae KB, Choi CS, Hwang JW, et al. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy. World J Surg Oncol. 2015;13:64.","journal-title":"World J Surg Oncol"},{"key":"1188_CR21","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/sj.bjc.6602426","volume":"92","author":"D Goldstein","year":"2005","unstructured":"Goldstein D, Mitchell P, Michael M, Beale P, Friedlander M, Zalcberg J, et al. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer 2005;92:832\u20137.","journal-title":"Br J Cancer"},{"key":"1188_CR22","first-page":"79","volume":"3","author":"BR Hirsch","year":"2011","unstructured":"Hirsch BR, Yousuf Zafar S. Capecitabine in the management of colorectal cancer. Cancer Manag Res. 2011;3:79\u201389.","journal-title":"Cancer Manag Res"},{"key":"1188_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1021\/acs.chemrestox.6b00215","volume":"29","author":"Y Lou","year":"2016","unstructured":"Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, et al. Possible pathways of capecitabine-induced hand\u2013foot syndrome. Chem Res Toxicol. 2016;29:1591\u2013601.","journal-title":"Chem Res Toxicol"},{"key":"1188_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/sonc.2002.35524","volume":"29","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Misset J-L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29:11\u201320.","journal-title":"Semin Oncol"},{"key":"1188_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3393\/jksc.2011.27.3.140","volume":"27","author":"H-J Jeon","year":"2011","unstructured":"Jeon H-J, Woo J-H, Lee H-Y, Park K-J, Choi H-J. Adjuvant chemotherapy using the FOLFOX regimen in colon cancer. J Korean Soc Coloproctol. 2011;27:140\u20136.","journal-title":"J Korean Soc Coloproctol"},{"key":"1188_CR26","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/bjc.2012.434","volume":"107","author":"R-D Hofheinz","year":"2012","unstructured":"Hofheinz R-D, Heinemann V, von Weikersthal LF, Laubender RP, Gencer D, Burkholder I, et al. Capecitabine-associated hand\u2013foot\u2013skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer 2012;107:1678\u201383.","journal-title":"Br J Cancer"},{"key":"1188_CR27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.6004\/jnccn.2015.0152","volume":"13","author":"C Owusu","year":"2015","unstructured":"Owusu C, Cohen HJ, Feng T, Tew W, Mohile SG, Klepin HD, et al. Anemia and functional disability in older adults with cancer. J Natl Compr Canc Netw. 2015;13:1233\u20139.","journal-title":"J Natl Compr Canc Netw"},{"key":"1188_CR28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3109\/00365521.2013.781216","volume":"48","author":"I Fj\u00f8rtoft","year":"2013","unstructured":"Fj\u00f8rtoft I, Furnes B, Hausken T, Storli KE, Eide GE, S\u00f8ndenaa K. Pre-operative anemia in colon cancer patients became normal after more than a year post-operatively but did not influence oncological outcome in the final analysis. Scand J Gastroenterol. 2013;48:663\u201371.","journal-title":"Scand J Gastroenterol"},{"key":"1188_CR29","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.7314\/APJCP.2015.16.6.2355","volume":"16","author":"I Hacibekiroglu","year":"2015","unstructured":"Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Uzunoglu S, Cicin I. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil\/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status. Asian Pac J Cancer Prev. 2015;16:2355\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1188_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4143\/crt.2010.42.4.185","volume":"42","author":"KK Baek","year":"2010","unstructured":"Baek KK, Lee J, Park SH, Park JO, Park YS, Lim HY, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat. 2010;42:185\u201390.","journal-title":"Cancer Res Treat"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1188-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T19:21:39Z","timestamp":1565896899000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1188-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1188-2","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"3 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the Ethical Standards of the Institutional and\/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Specifically, the Health Research Ethics Board (HREB) approved this study before its conduct.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Because this study was a secondary analysis of retrospective data, there was no direct contact with any participants. Therefore, informed consent was waived by the Ethics Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"125"}}